RecruitingNot ApplicableNCT07583784

Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI

Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction

Sponsor

Chonnam National University Hospital

Enrollment

860 participants

Start Date

Aug 26, 2026

Study Type

INTERVENTIONAL

Conditions

Myocardial Infarction (MI)AF - Atrial Fibrillation ST-segment elevation myocardial infarction (STEMI)NSTEMI - Non-ST-Segment Elevation Myocardial Infarction

Summary

The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DAT (DOAC+clopidogrel) and a drug called DOAC monotherapy for people with af - atrial fibrillation, myocardial infarction (mi), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDAT (DOAC+clopidogrel)

Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.

DRUGDOAC monotherapy

Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.